Pablo A Valdés1,2,3,4, Valerie Jacobs5,2, Brent T Harris6, Brian C Wilson7, Frederic Leblond8, Keith D Paulsen4, David W Roberts2,3. 1. Department of Neurosurgery, Brigham and Women's/Boston Children's Hospitals, Harvard Medical School; 2. Geisel School of Medicine at Dartmouth, Hanover; 3. Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, Lebanon; 4. Thayer School of Engineering, Hanover, New Hampshire; 5. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts; 6. Georgetown University Medical Center, Washington, DC; 7. Ontario Cancer Institute, University of Toronto, Ontario; and. 8. Department of Engineering Physics, Polytechnique Montreal, Quebec, Canada.
Abstract
OBJECT: Previous studies in high-grade gliomas (HGGs) have indicated that protoporphyrin IX (PpIX) accumulates in higher concentrations in tumor tissue, and, when used to guide surgery, it has enabled improved resection leading to increased progression-free survival. Despite the benefits of complete resection and the advances in fluorescence-guided surgery, few studies have investigated the use of PpIX in low-grade gliomas (LGGs). Here, the authors describe their initial experience with 5-aminolevulinic acid (ALA)-induced PpIX fluorescence in a series of patients with LGG. METHODS: Twelve patients with presumed LGGs underwent resection of their tumors after receiving 20 mg/kg of ALA approximately 3 hours prior to surgery under an institutional review board-approved protocol. Intraoperative assessments of the resulting PpIX emissions using both qualitative, visible fluorescence and quantitative measurements of PpIX concentration were obtained from tissue locations that were subsequently biopsied and evaluated histopathologically. Mixed models for random effects and receiver operating characteristic curve analysis for diagnostic performance were performed on the fluorescence data relative to the gold-standard histopathology. RESULTS: Five of the 12 LGGs (1 ganglioglioma, 1 oligoastrocytoma, 1 pleomorphic xanthoastrocytoma, 1 oligodendroglioma, and 1 ependymoma) demonstrated at least 1 instance of visible fluorescence during surgery. Visible fluorescence evaluated on a specimen-by-specimen basis yielded a diagnostic accuracy of 38.0% (cutoff threshold: visible fluorescence score ≥ 1, area under the curve = 0.514). Quantitative fluorescence yielded a diagnostic accuracy of 67% (for a cutoff threshold of the concentration of PpIX [CPpIX] > 0.0056 μg/ml, area under the curve = 0.66). The authors found that 45% (9/20) of nonvisibly fluorescent tumor specimens, which would have otherwise gone undetected, accumulated diagnostically significant levels of CPpIX that were detected quantitatively. CONCLUSIONS: The authors' initial experience with ALA-induced PpIX fluorescence in LGGs concurs with other literature reports that the resulting visual fluorescence has poor diagnostic accuracy. However, the authors also found that diagnostically significant levels of CPpIX do accumulate in LGGs, and the resulting fluorescence emissions are very often below the detection threshold of current visual fluorescence imaging methods. Indeed, at least in the authors' initial experience reported here, if quantitative detection methods are deployed, the diagnostic performance of ALA-induced PpIX fluorescence in LGGs approaches the accuracy associated with visual fluorescence in HGGs.
OBJECT: Previous studies in high-grade gliomas (HGGs) have indicated that protoporphyrin IX (PpIX) accumulates in higher concentrations in tumor tissue, and, when used to guide surgery, it has enabled improved resection leading to increased progression-free survival. Despite the benefits of complete resection and the advances in fluorescence-guided surgery, few studies have investigated the use of PpIX in low-grade gliomas (LGGs). Here, the authors describe their initial experience with 5-aminolevulinic acid (ALA)-induced PpIX fluorescence in a series of patients with LGG. METHODS: Twelve patients with presumed LGGs underwent resection of their tumors after receiving 20 mg/kg of ALA approximately 3 hours prior to surgery under an institutional review board-approved protocol. Intraoperative assessments of the resulting PpIX emissions using both qualitative, visible fluorescence and quantitative measurements of PpIX concentration were obtained from tissue locations that were subsequently biopsied and evaluated histopathologically. Mixed models for random effects and receiver operating characteristic curve analysis for diagnostic performance were performed on the fluorescence data relative to the gold-standard histopathology. RESULTS: Five of the 12 LGGs (1 ganglioglioma, 1 oligoastrocytoma, 1 pleomorphic xanthoastrocytoma, 1 oligodendroglioma, and 1 ependymoma) demonstrated at least 1 instance of visible fluorescence during surgery. Visible fluorescence evaluated on a specimen-by-specimen basis yielded a diagnostic accuracy of 38.0% (cutoff threshold: visible fluorescence score ≥ 1, area under the curve = 0.514). Quantitative fluorescence yielded a diagnostic accuracy of 67% (for a cutoff threshold of the concentration of PpIX [CPpIX] > 0.0056 μg/ml, area under the curve = 0.66). The authors found that 45% (9/20) of nonvisibly fluorescent tumor specimens, which would have otherwise gone undetected, accumulated diagnostically significant levels of CPpIX that were detected quantitatively. CONCLUSIONS: The authors' initial experience with ALA-induced PpIX fluorescence in LGGs concurs with other literature reports that the resulting visual fluorescence has poor diagnostic accuracy. However, the authors also found that diagnostically significant levels of CPpIX do accumulate in LGGs, and the resulting fluorescence emissions are very often below the detection threshold of current visual fluorescence imaging methods. Indeed, at least in the authors' initial experience reported here, if quantitative detection methods are deployed, the diagnostic performance of ALA-induced PpIX fluorescence in LGGs approaches the accuracy associated with visual fluorescence in HGGs.
Authors: Pablo A Valdes; Kimon Bekelis; Brent T Harris; Brian C Wilson; Frederic Leblond; Anthony Kim; Nathan E Simmons; Kadir Erkmen; Keith D Paulsen; David W Roberts Journal: Neurosurgery Date: 2014-03 Impact factor: 4.654
Authors: Christian Ewelt; Frank W Floeth; Jörg Felsberg; Hans J Steiger; Michael Sabel; Karl-Josef Langen; Gabriele Stoffels; Walter Stummer Journal: Clin Neurol Neurosurg Date: 2011-04-20 Impact factor: 1.876
Authors: Matthew J McGirt; Kaisorn L Chaichana; Frank J Attenello; Jon D Weingart; Khoi Than; Peter C Burger; Alessandro Olivi; Henry Brem; Alfredo Quinoñes-Hinojosa Journal: Neurosurgery Date: 2008-10 Impact factor: 4.654
Authors: David W Roberts; Jonathan D Olson; Linton T Evans; Kolbein K Kolste; Stephen C Kanick; Xiaoyao Fan; Jaime J Bravo; Brian C Wilson; Frederic Leblond; Mikael Marois; Keith D Paulsen Journal: J Neurosurg Date: 2017-08-04 Impact factor: 5.115
Authors: Evgenii Belykh; Eric J Miller; Danying Hu; Nikolay L Martirosyan; Eric C Woolf; Adrienne C Scheck; Vadim A Byvaltsev; Peter Nakaji; Leonard Y Nelson; Eric J Seibel; Mark C Preul Journal: World Neurosurg Date: 2018-02-02 Impact factor: 2.104
Authors: Brian W Pogue; Keith D Paulsen; Kimberley S Samkoe; Jonathan T Elliott; Tayyaba Hasan; Theresa V Strong; Daniel R Draney; Joachim Feldwisch Journal: Med Phys Date: 2016-06 Impact factor: 4.071
Authors: Mira Sibai; Dennis J Wirth; Frederic Leblond; David W Roberts; Keith D Paulsen; Brian C Wilson Journal: J Biophotonics Date: 2019-03-20 Impact factor: 3.207